ZUMA-7 研究的通俗语言摘要：axicabtagene ciloleucel 对比标准治疗用于复发/难治性大 B 细胞淋巴瘤患者

What is this summary about? This is a summary of a clinical study called ZUMA-7. ZUMA-7 looked at how the anti-cancer therapy axicabtagene ciloleucel (axi-cel) compared with standard treatment for people with large B-cell lymphoma (LBCL). LBCL is a cancer that affects a type of white blood cell called B cells. Axi-cel is a type of chimeric antigen receptor (CAR) T-cell therapy. This treatment is made from a person s own immune cells and uses a person s natural immune defences to fight cancer. How was the study conducted? The ZUMA-7 study was made up of 359 people whose LBCL came back (relapsed) within a year or did not fully respond (refractory) to their first cancer treatment plan. People in the study were randomly put into 2 treatment groups. 180 people were to get axi-cel,and 179 were to get standard-of-care treatment, which was chemotherapy and autologous stem cell transplantation. Before the results of ZUMA-7, this standard treatment was the most effective treatment for people with LBCL whose first treatment did not work.

The researchers in ZUMA-7 determined the benefit of axi-cel by looking at how well the treatment worked and what side effects (toxicity) people had in the axi-cel group compared with the standard-of-care group. What were the results? At 2 years since joining the study, people in the axi-cel group lived without their cancer getting worse or needing new cancer treatment for a median time of about 8 months, compared with 2 months for people in the chemotherapy-based standard-of-care group.

Most people in the axi-cel group were still alive after 4 years, but half the people in the standard-of-care group had died within about 31 months of treatment. The most common side effects from axi-cel were caused by an overactive immune system and What do the results mean? People with relapsed or refractory LBCL live longer and have better control of their cancer when treated with axi-cel compared with chemotherapy-based standard of care as their second anti-cancer treatment. [Box: see text].